Tarsus Pharmaceuticals’ (TARS) “Buy” Rating Reaffirmed at Guggenheim

Guggenheim reaffirmed their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS) in a report published on Monday,Benzinga reports.

Several other brokerages have also recently issued reports on TARS. Barclays increased their price objective on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, The Goldman Sachs Group raised their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $56.00.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $51.76 on Monday. Tarsus Pharmaceuticals has a 52-week low of $20.08 and a 52-week high of $57.28. The business has a fifty day moving average of $52.03 and a two-hundred day moving average of $41.04. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -13.59 and a beta of 1.01. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Institutional Trading of Tarsus Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its stake in shares of Tarsus Pharmaceuticals by 10.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,282 shares of the company’s stock worth $905,000 after buying an additional 3,112 shares during the last quarter. SG Americas Securities LLC raised its position in Tarsus Pharmaceuticals by 87.5% during the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after acquiring an additional 3,379 shares during the last quarter. Creative Planning purchased a new stake in shares of Tarsus Pharmaceuticals in the third quarter valued at about $362,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 16.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company’s stock valued at $6,924,000 after purchasing an additional 29,465 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in shares of Tarsus Pharmaceuticals by 7.3% in the third quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock valued at $37,536,000 after purchasing an additional 77,825 shares during the last quarter. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.